DR ANTHONY MELVIN CRASTO,WorldDrugTracker, helping millions, A 90 % paralysed man in action for you, I am suffering from transverse mylitis and bound to a wheel chair, With death on the horizon, nothing will not stop me except God................DR ANTHONY MELVIN CRASTO Ph.D ( ICT, Mumbai) , INDIA 25Yrs Exp. in the feld of Organic Chemistry,Working for GLENMARK GENERICS at Navi Mumbai, INDIA. Serving chemists around the world. Helping them with websites on Chemistry.Million hits on google, world acclamation from industry, academia, drug authorities for websites, blogs and educational contribution
Showing posts with label JAFFNA. Show all posts
Showing posts with label JAFFNA. Show all posts

Thursday 9 April 2015

VENLAFAXINE PART 3/3



SEE


PAPER
RSC Adv., 2014,4, 14468-14470
DOI: 10.1039/C4RA00840E
A protecting group free asymmetric total synthesis of (−)-venlafaxine is reported. The strategy employs Sharpless epoxidation and regio-selective epoxide ring opening by an in situgenerated Gilman reagent as key steps. This paper reports a 53% overall yield in 6 steps for total synthesis of (−)-venlafaxine.

Graphical abstract: A protecting group free and scalable approach towards total synthesis of (−)-venlafaxine
…………………






















Displaying image038.png

Displaying image039.png

Displaying image040.png



Displaying image041.png




Displaying image043.png


Displaying image044.png


Displaying image045.png




Displaying image046.png



Displaying image047.png

Displaying image024.png




Displaying image025.png



Displaying image026.png



Displaying image027.png






Displaying image028.png


Displaying image029.png




Displaying image030.png


Displaying image031.png



Displaying image032.png


Displaying image033.png



Displaying image034.png






JAFFNA SRILANKA



Map of jaffna sri lanka


Image result for JAFFNA



































Thursday 2 April 2015

LINEZOLID IMPURITIES

Skeletal formula of linezolid

LINEZOLID
N- [[(5S) - 3 - [3 -Fluoro-4- (4-morpholinyl)phenyl] -2-oxo- 5 -oxazolidinyl] methyl] acetamide and marketed by Pfizer in US under brand name Zyvox. Linezolid is a synthetic antibacterial agent of the oxazolidinone class. It is used for the treatment of infections caused by multi-resistant bacteria including streptococci and methicillin-resistant Staphylococcus aureus.


(S)-N-[[3-(3-fluoro-4-morpholinylphenyl)-2-oxo-5-oxazolidinyl]methyl] acetamide. 
N-[[(5s)-3-(3-fluoro-4-morpholin-4-ylphenyl)-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide
PRODUCT PATENT

US 5688792 (1997 to Pharmacia & Upjohn)


CAS No.:165800-03-3
Synonyms:

Formula:C16H20FN3O4
Exact Mass:337.14400








13C




1H NMR AND 13C PREDICT









1H NMR PREDICT

N-[[(5S)-3-(3-fluoro-4-morpholin-4-ylphenyl)-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide NMR spectra analysis, Chemical CAS NO. 165800-03-3 NMR spectral analysis, N-[[(5S)-3-(3-fluoro-4-morpholin-4-ylphenyl)-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide H-NMR spectrum



13C NMR PREDICT

N-[[(5S)-3-(3-fluoro-4-morpholin-4-ylphenyl)-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide NMR spectra analysis, Chemical CAS NO. 165800-03-3 NMR spectral analysis, N-[[(5S)-3-(3-fluoro-4-morpholin-4-ylphenyl)-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide C-NMR spectrum

COSY
PREDICT




HMBC









ORIGINAL 1H NMR...............http://www.selleckchem.com/products/Linezolid(Zyvox).html




INTERMEDIATES USED


Arkivoc, , vol. 2012, # 6 p. 45 - 56

WO2011/137222 A1, ;


Union Quimico Farmaceutica, S.A. (UQUIFA) Patent: EP2163547 A1, 2010 ; Location in patent: Page/Page column 11 ;





THE REGENTS OF THE UNIVERSITY OF CALIFORNIA; GARG, Neil K.; RAMGREN, Stephen D.; SILBERSTEIN, Amanda L.; QUASDORF, Kyle W. Patent: WO2012/94622 A2, 2012 ; Location in patent: Page/Page column 31-32 ;





Lianhe Chemical Technology Co., Ltd. Patent: EP2388251 A1, 2011 ; Location in patent: Page/Page column 11 ;









Tammana, Rajesh; Vemula, Kiran Kumar; Guruvindapalli, Ramadasu; Yanamandr, Ramesh; Gutta, Madhusudhan Arkivoc, 2012 , vol. 2012, # 6 p. 45 - 56





Union Quimico Farmaceutica, S.A. (UQUIFA) Patent: EP2163547 A1, 2010 ; Location in patent: Page/Page column 10 ;




Song, Lirong; Chen, Xiaobei; Zhang, Shilei; Zhang, Haoyi; Li, Ping; Luo, Guangshun; Liu, Wenjing; Duan, Wenhu; Wang, Wei Organic Letters, 2008 , vol. 10, # 23 p. 5489 - 5492





Union Quimico Farmaceutica, S.A. (UQUIFA) Patent: EP2163547 A1, 2010 ; Location in patent: Page/Page column 10 ;




JUBILANT LIFE SCIENCES LIMITED; BISWAS, Sujay; PANDA, Atulya, Kumar; GUPTA, Ashish, Kumar; SINGH, Shishupal; TIWARI, Praveen; VIR, Dharam; THOMAS, Saji Patent: WO2013/111048 A1, 2013 ; Location in patent: Page/Page column 24; 25 ;




Perrault, William R.; Pearlman, Bruce A.; Godrej, Delara B.; Jeganathan, Azhwarsamy; Yamagata, Koji; Chen, Jiong J.; Lu, Cuong V.; Herrinton, Paul M.; Gadwood, Robert C.; Chan, Lai; Lyster, Mark A.; Maloney, Mark T.; Moeslein, Jeffery A.; Greene, Meredith L.; Barbachyn, Michael R. Organic Process Research and Development, 2003 , vol. 7, # 4 p. 533 - 546




US6362334 B1, ; Example 13 ;











NMR OF INTERMEDTIATES



.............



.......





.........





...............




...............




  • Linezolid is a pharmaceutically active compound useful as an antibacterial agent, e.g. for the treatment of diabetic food infections caused by Gram-positive bacteria. It is represented by the formula (I),
    Figure imgb0001
  • [0003]
    The marketed pharmaceutical compositions are a sterile isotonic solution for an i.v. infusion, a tablet for oral administration and an aqueous suspension for oral administration. They are marketed, i.e., under brand name ZYVOX by Pfizer.
  • [0004]
    The molecule of linezolid has one asymmetric carbon in the molecule allowing for 2 enantiomers; the marketed compound is the (S)-enantiomer. In the above-marketed compositions, linezolid is present as a free base.
  • [0005]
    Hereinunder, the name linezolid will be used as the generic name for N-(3-(3-fluoro-4-(morpholin-4-yl)phenyl)-2-oxooxazolidin-5(S)-ylmethyl)acetamide, unless indicated to the contrary.
  • [0006]
    Linezolid was first disclosed in WO 95/07271 ( EP 0717738 US 5,688,792 ) of the Upjohn Company.
  • [0007]
    Various processes for making linezolid are known in the art. In particular, the important ones are these, the final step of which comprises acetylation of an amine precursor of the formula (II) with an acetylhalide or acetic anhydride (see, e.g., WO 2005 099353 ),
    Figure imgb0002
  • [0008]
    This amine precursor (II) may be made from various starting materials, e.g.:
    1. a) By a reduction of an azide compound of formula (III) by a suitable reductant ( WO2006/091731 WO 95/07271 US 5837870 , WO2009/063505 US 7291614 ),
      Figure imgb0003
      The starting compound (III) may be made from the corresponding tosylate or chloride of general formula (VII) below ( WO 2005/099353 ).
    2. b) By a decomposition of a phthalimide compound of formula (IV), e.g. by methylamine ( WO95/07271 ) or by hydrazine ( US 5837870 ),
      Figure imgb0004
      The starting compound (IV) may be made from the same tosylate or chloride as sub a) ( WO2005/099353 ) or by a cyclization of the oxazolidine ring ( WO 99/24393 WO2006/008754 ).
    3. c) From a sulfonate compound of formula (V),
      Figure imgb0005
      by treatment with ammonium hydroxide in isopropanol or THF ( WO 95/07271 ) or by treatment with ammonia under enhanced pressure ( WO 97/37980 ).
    4. d) By a reduction of an imine (VI),
      Figure imgb0006
      wherein R2 is a chlorophenyl, bromophenyl or 2,4,-dichlorophenyl moiety ( WO 2007/116284 ).
  • [0009]
    Except of the imine (VI), each of the preceded synthetic approaches is based on a step of converting a starting material of the general formula (VII),
    Figure imgb0007
    wherein L is a suitable leaving group, for instance a halogen or an alkyl-or aryl sulfonyloxy group,
    by a reaction with a nitrogen nucleophile (an azide salt, phthalimide salt, ammonia or ammonium hydroxide), followed, if necessary, by a next step of conversion of the formed reaction intermediate (e.g., compound (III) or compound (IV)) into the amino/compound (II). Apparently, making the starting amine-compound (II) in a good yield and purity is the key aspect of commercial success of any of the above synthetic routes yielding linezolid. However, the known approaches have various drawbacks, for instance serious toxicity and explosion hazard of the azide salts, long reaction times and hazardous agents (hydrazine, methyl amine) in using the phthalimide intermediate, low yields and many side products at the ammonium hydroxide approach, or harsh reaction conditions in reaction with ammonia.




Linezolid [(S)-N-[[3-(3-Fluoro-4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide] is an antimicrobial agent. Linezolid is an oxazolidinone, having the empirical formula C16H20FN3Oand the following structure (1):
Figure US20060252932A1-20061109-C00001
Linezolid (1) is described in The Merck Index (13th edition, Monograph number: 05526, CAS Registry Number: 165800-03-3) as white crystals, with a melting point of 181.5-182.5°. Linezolid (1), as well as a process for its preparation, is disclosed in U.S. Pat. No. 5,688,792 (Example 5), European Patent No. 717738, Israeli Patent No. 110,802, Canadian Patent No. 2,168,560, and International Patent Publication WO 95/07271.

U.S. Pat. No. 5,688,792 discloses the antibacterial agent linezolid as well as a process for its preparation. EXAMPLE 5 reports the linezolid produced had a mp of 181.5-182.5°.
There are many other disclosures of processes to prepare linezolid. J. Med. Chem., 39(3), 673-9 (1996) reports the linezolid was, “recrystallized from ethyl acetate and hexanes . . . white crystals, m.p. 181.5-182.5C.” It also sets forth the IR spectrum as “3284, 3092, 1753, 1728, 1649, 1565, 1519, 1447, 1435”.
Tetrahedron Lett., 40(26), 4855 (1999) discloses linezolid and a process to prepare linezolid. However, this document does not set forth the melting point or IR spectrum of the linezolid prepared.
U.S. Pat. No. 5,837,870 (International Publication WO97/37980 of PCT/US97/03458) discloses a process to prepare linezolid. Linezolid is described in EXAMPLE 18, which does not set forth the melting point or IR spectrum of the linezolid prepared.
International Publication WO99/24393 of PCT/US98/20934 discloses a process to prepare linezolid. Linezolid is described in EXAMPLES 8, 9 and 12 which do no set forth the melting point or IR spectrum of the linezolid prepared.
The form of linezolid being used in the clinical trials to support the filing of the NDA is Form II.



Linezolid (1) is marketed in the United States by Pfizer, Inc. as an injection, tablets, and oral suspension under the name ZYVOX®. Its main indications are nosocomial pneumonia, skin and skin-structure infections, and vancomycin-resistant Enterococcus faecium infections.
U.S. Pat. No. 5,688,792 claims linezolid (1) and its use for the treatment of microbial infections. This patent also discloses, but does not claim, the following method of preparation:
Figure US20060252932A1-20061109-C00002
This method of preparation was also disclosed in Bricker, et al., J. Med. Chem., 39 673 -679 (1996), where it was stated that the above route avoids the use of phosgene to make the carbamate precursor of the oxazolidinone ring. The authors also disclose that the use of NaNcan be avoided by using potassium phthalimide, followed by deblocking of the phthalimide with aqueous methyl amine.
In the above-described synthesis, the intermediate amine, S-N-(4-morpholinyl-3-fluorophenyl)-2-oxo-5-oxazolidinyl-methyl amine (2)
Figure US20060252932A1-20061109-C00003

is reacted without isolation with acetic anhydride as an oily product, or in solution, to produce the acetamide, linezolid (1). This is followed by procedures for isolating the linezolid (1) such as those described in U.S. Pat. No. 5,688,792, at col. 15, 11. 22-28 (chromatography and separation of the desired fraction, followed by evaporation and trituration of the product to obtain pure linezolid (1)).
In the above-described syntheses, the intermediate azide R-N-(4-morpholinyl-3-fluorophenyl)-2-oxo-5-oxazolidinyl-methyl azide (3)
Figure US20060252932A1-20061109-C00004

is reduced to its corresponding amine, S-N-(4-morpholinyl-3-fluorophenyl)-2-oxo-5-oxazolidinyl-methyl amine (2) in the solvent ethyl acetate by hydrogenation using hydrogen gas and a palladium/carbon catalyst. These reaction conditions lead to the production of an undesirable level of reaction by-products, and, following the acetylation of the intermediate amine (2) to linezolid (1), to undesirably high levels of bis-linezolid (4)
Figure US20060252932A1-20061109-C00005


http://www.google.com/patents/US20060252932
FIG. 1 shows the 1H-NMR spectrum of bis-linezolid (4)





FIG. 2 shows the 13C-NMR spectrum of bis-linezolid (4)







FIG. 3 shows the IR spectrum of bis-linezolid (4)





A Novel Synthesis of Oxazolidinone Derivatives (A Key Intermediate of Linezolid)


Pingili Krishna Reddy1,2, K. Mukkanti2 and Dodda Mohan Rao1*

1Symed Research Centre, Plot No. 89/A, Phase-I, Shapoornagar, IDA Jeedimetla, Hyderabad, Andhra Pradesh, India
2Center for Pharmaceutical sciences, Jawaharlal Nehru Technological University, Kukatpally, Hyderabad, India
http://www.orientjchem.org/vol29no3/a-novel-synthesis-of-oxazolidinone-derivatives-a-key-intermediate-of-linezolid/




Reddy P. K, Mukkanti K, Rao D. M. A Novel Synthesis of Oxazolidinone Derivatives (A Key Intermediate of Linezolid). Orient J Chem 2013;29(3). doi : http://dx.doi.org/10.13005/ojc/290322

N-[[(5S)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide (7a):

 IR (KBr, cm-1): 3338 (N-H stretching), 3117, 3066 (aromatic C-H stretching), 2971, 2863, 2818 (aliphatic C-H stretching), 1738, 1662 (C=O stretching), 1545, 1516,1453 (aromatic C=C stretching), 1425 (C-N stretching), 1381 (aliphatic C-H bending), 1334 (C-F stretching), 1274 (C-O stretching), 1198, 1177 (C-N bending), 1117, 1081 (aromatic C-H bending).


1H NMR (CDCl3) δ ppm: 7.44 (m, 1H), 7.26 (m, 1H), 6.99 (m, 1H), 6.01 (t,1H), 4.76 (m, 1H), 4.02 (m, 2H), 3.80 (m, 4H), 3.61(m, 2H), 3.05 (m, 4H), 2.02 (t, 3H): 













C13NMR(CDCl3) δppm: 171.33, 156.87, 154.44, 136.40, 132.84, 118.67, 113.81, 107.52, 71.96, 66.76, 50.79, 47.46, 41.68, 22.81. MS: 338 (M++H);




..................................................................................




ARKIVOC 2012 (vi) 45-56 Page 45 ©ARKAT-USA, Inc.

 An expeditious construction of 3-aryl-5-(substituted methyl)-2- oxazolidinones: a short and efficient synthesis of Linezolid

Rajesh Tammana,a,b Kiran Kumar Vemula,a Ramadasu Guruvindapalli,a Ramesh Yanamandra,c and Madhusudhan Gutta* a
aDepartment of Research & Development, Inogent Laboratories Pvt. Ltd.,

A GVK BIO Company, 28A, IDA, Nacharam, Hyderabad 500 076, Andhra Pradesh, India


bCentre for Pharmaceutical Sciences, Institute of Science and Technology, Jawaharlal Nehru Technological University, Hyderabad 500 072, Andhra Pradesh, India

cDepartment of Analytical Research & Development, GVK Biosciences Pvt. Ltd., 28A, IDA, Nacharam, Hyderabad 500 076, Andhra Pradesh, India

 E-mail: madhusudhan.gutta@inogent.com


http://www.arkat-usa.org/get-file/42622/
N-(((S)-3-(3-fluoro-4-morpholinophenyl)-2-oxooxazolidin-5-yl)methyl)acetamide 1 (Linezolid) 1 was prepared according to the method described in literature.12,15

Mp 182-183 °C, (lit.12a 181.5- 182.5 °C); enantiomeric purity 99.9% (by chiral HPLC);

IR (KBr): ν 3343 (NH), 3075 (Ar-H), 2967 (CH), 1741 (C═O), 1660 (C═O) cm-1 ;

1H NMR (CDCl3): δ 2.03 (s, 3H), 3.04-3.07 (t, 4H), 3.56-3.77 (m, 3H), 3.86-3.89 (t, 4H), 4.00-4.06 (t, 1H), 4.74-4.79 (m, 1H), 5.96 (s, 1H), 6.90- 6.96 (t, 1H), 7.06-7.10 (d, 1H), 7.43-7.48 (d, 1H).

13C NMR (DMSO-d6): δ 22.4, 41.4, 47.3, 50.6, 66.1, 71.5, 106.4, 114.0, 119.1, 133.3, 135.5, 154.0, 156.2, 170.0;

ESI-MS (C16H20FN3O4): m/z (%) 338.18 (100, M+ +1).



12. (a) Brickner, S. J.; Hutchinson, D. K.; Barbachyn, M. R.; Manninen, P. R.; Ulanowicz, D. A.;
Garmon, S. A.; Grega, K. C.; Hendges, S. K.; Toops, D. S.; Ford, C. W.; Zurenko, G. E. J.
Med. Chem. 1996, 39, 673. (b) Barbachyn, M. R.; Brickner, S. J.; Hutchinson, D. K. U.S.
patent 5688792; 1997; Chem. Abstr. 1995, 123, 256742. (c) Dhananjay, G. S.; Nandu, B. B.;
Avinash, V. N.; Kamlesh, D. S.; Anindya, S. B.; Tushar, A. N. PCT Int. Appl. 063505, 2009;
Chem. Abstr. 2009, 150, 515152.
13. (a) Imbordino, R. J.; Perrault, W. R.; Reeder, M. R. PCT Int. Appl. 116284, 2007; Chem.
Abstr. 2007, 147, 469356. (b) Pearlman, B. A.; Perrault, W. R.; Barbachyn, M. R.;
Manninen, P. R.; Toops, D. S.; Houser, D. J.; Fleck, T. J. U.S. Patent 5837870, 1998; Chem.
Abstr. 1998, 130, 25061. (c) Perrault, W. R.; Pearlman, B. A.; Godrej, D. B.; Jeganathan, A.;
Yamagata, K.; Chen, J. J.; Lu, C. V.; Herrinton, P. M.; Gadwood, R. C.; Chan, L.; Lyster, M.
A.; Maloney, M. T.; Moeslein, J. A.; Greene, M. L.; Barbachyn, M. R. Org. Proc. Res. Dev.
2003, 7, 533.
14. (a) Yu, D. S.; Huang, L.; Liang, H.; Gong, P. Chin. Chem. Lett. 2005, 16, 875. (b) Pearlman,
B. A. PCT Int. Appl. 9924393, 1999; Chem. Abstr. 1999, 130, 338099. (c) Weigert, F. J. J.
Org. Chem. 1973, 38, 1316.
15. (a) Wang, M.; Tong, H. CN patent 101220001, 2008. (b) Mohan Rao, D.; Krishna Reddy, P.
PCT Int. Appl. 099353, 2005; Chem. Abstr. 2005, 143, 440395. (c) Mohan Rao, D.; Krishna
Reddy, P. PCT Int. Appl. 008754, 2006; Chem. Abstr. 2006, 144, 170978.

..........................................
Org. Proc. Res. Dev.20037 (4), pp 533–546
DOI: 10.1021/op034028h

Organic Process Research and Development, 2003 , vol. 7, # 4 p. 533 - 546

http://pubs.acs.org/doi/abs/10.1021/op034028h
Abstract Image
Since 1993, a significant process research and development effort directed towards the large-scale synthesis of oxazolidinone antibacterial agents has been ongoing in both Early Chemical Process Research and Development, and Chemical Process Research and Development at Pharmacia. This work has led to the successful development of the current commercial process to produce Zyvox (linezolid), recently approved by the FDA as an antibacterial. While this synthesis is appropriate for the preparation of linezolid in particular, a more convergent and versatile synthesis was developed for the rapid preparation of numerous other oxazolidinone analogues. Toward this end, economical methods for the large-scale preparation of N-[(2S)-2-(acetyloxy)-3-chloropropyl]acetamide and tert-butyl [(2S)-3-chloro-2-hydroxypropyl]carbamate 27 from commercially available (S)-epichlorohydrin via the common intermediate (2S)-1-amino-3-chloro-2-propanol hydrochloride 2a were developed. Also, general methods for coupling these reagents with N-aryl carbamates to giveN-aryl-5(S)-aminomethyl-2-oxazolidinone derivatives in one step were developed. These reagents and procedures have proven widely applicable in the preparation of a diverse array of oxazolidinone analogues such as 23 and 28 in both process and medicinal chemistry research.



(S)-N-[[3-[3-Fluoro-4-(4-morpholinyl)phenyl]-2-oxo- 5-oxazolidinyl]methyl]acetamide: Linezolid: Zyvox

 HPLC analyses showed the first and second crops to be 98.9 and 94.6 wt % linezolid, respectively, with <0.2% enantiomer in each; also, an additional 9.7% yield of linezolid was detected in the filtrate by external standard HPLC (total ) 80.6%). Analysis data for 1st crop material: mp ) 73-76 °C; 

1 H NMR (CDCl3, 400 MHz) 
δ 7.43 (dd, J ) 14.4, 2.4 Hz, 1H), 7.07 (dd, J ) 8.8, 2.0 Hz, 1H), 6.91 (t, J ) 8.8 Hz, 1H), 6.43 (br t, 1H), 4.77 (m, 1H), 4.02 (t, J ) 9.2 Hz, 1H), 3.86 (t, J ) 4.4 Hz, 4H), 3.76 (dd, J ) 8.8, 6.8 Hz, 1H), 3.66 (m, 2H), 3.05 (t, J ) 4.8 Hz, 4H), 2.02 (s, 3H); 


13C NMR (CDCl3, 100 MHz) 
δ 23.07 (q), 41.93 (t), 47.66 (t), 51.00 (t), 66.95 (t), 71.99 (d), 107.56 (dd, JC-F ) 26.16 Hz), 113.97 (dd, JC-F ) 3.02 Hz), 118.85 (dd, JC-F ) 4.03 Hz), 132.90 (sd, JC-F ) 4.03 Hz), 136.58 (sd, JC-F ) 9.06 Hz), 154.42 (s), 155.50(sd, JC-F ) 246.53 Hz), 171.19 (s) 

MS (EI) m/z (relative intensity) 337 (90), 293 (81), 209 (100); 


[R]25D ) -16 (c ) 1.05, ethanol). 


Anal. Calcd for C16H20FN3O4: C, 56.97; H, 5.97; N, 12.46; found: C, 56.86; H, 6.05; N, 12.44


HPLC (99.0 wt %, 98.9 area % linezolid, tR 1.60 min) conditions: InertsilODS-2 5.0 µm 150 mm × 4.6 mm, flow rate ) 2.0 mL/ min, gradient elution from 40:60 A:B to 80:20 A:B over 10 min; A ) acetonitrile; B ) water. External standard HPLC analysis of the filtrate showed
d 12.9% and 7.6% yield of linezolid and 8, respectively.
SEE HPLC AT   http://file.selleckchem.com/downloads/hplc/S140801-Linezolid-Zyvox-HPLC-Selleck.pdf
...............................
http://www.google.com/patents/WO2007064818A1?cl=en

Linezolid [(S)-N-[[3-(3-Fluoro-4-morpholinyl)phenyl]-2-oxo-5- oxazolidinyljmethyl] acetamide} is an antimicrobial agent. Linezolid is an oxazolidinone, having the empirical formula C16H20FN3O4 and the following structure:
Figure imgf000002_0001
Linezolid
Linezolid is described in The Merck Index (13th edition, Monograph number: 05526, CAS Registry Number: 165800-03-3) as white crystals, with a melting point of 181.5-182.50C. Linezolid, as well as a process for its preparation, is described in U.S. Patent No. 5,688,792 (Example 5), European Patent No. 717738, Israeli Patent No. 110,802, Canadian Patent No. 2,168,560, and International Patent Publication WO 95/07271. Linezolid is marketed in the United States by Pfizer, Inc. as an injection, as tablets, and as an oral suspension under the name ZYVOX®. Its main indications are nosocomial pneumonia, skin and skin-structure infections, and vancomycin-resistant Enterococcus faecium infections.
U.S. Patent No. 5,688,792 describes linezolid and its use for the treatment of microbial infections. This patent also describes the following method for the preparation of linezolid:
Figure imgf000003_0001
This method of preparation was also described in Bricker, et al., J. Med. Chem., 39, 673 — 679 (1996), where it was stated that the above route avoids the use of phosgene to make the carbamate precursor of the oxazolidinone ring. The authors also disclose that the use OfNaN3 can be avoided by using potassium phthalimide, followed by deblocking of the phthalimide with aqueous methyl amine.
An analysis of the commercial tablet ZYVOX® shows the presence of desfluoro linezolid as an impurity of linezolid. An HPLC chromatogram of ZYVOX® is depicted in Figure 1. The desfluoro linezolid haviong a relative retention time (RRT) of 0.69 compared to the retention time of linezolid.

desfluoro linezolid of the following structure:
Figure imgf000008_0001
Desfluoro linezolid
As illustrated in Figure 1, this impurity is ideal for use as a reference standard since it is detectable by HPLC, and yet it is present in much less amounts than linezolid, having a RRT of 0.69 compared to the retention time of linezolid.
The isolated desfluoro linezolid is pure. Preferably it has about 95% purity by weight with respect to other compounds, including linezolid. Preferably, the desfluoro linezolid is isolated in about 99.3% purity by weight. Thus, the isolated desfluoro linezolid contains less than about 5%, preferably less than about 2%, and even more preferably less than about 1%, by weight, linezolid.
The isolated desfluoro linezolid of the present invention can be characterized by data selected from: 1H NMR (400MHz, DMSO-d6) δ (ppm): 1.8a (s), 3.04 (brt), 3.40 (t), 3.68 (m), 3.72 (brt), 4.04 (t), 4.67 (m), 6.95 (d), 6.95 (d), 737 (d), 7.37 (d) and 8.21 (t); 13C NMR (lOOMHz, DMSO-d6) δ (ppm): 22.8, 41.9, 48.0, 49.2, 66.5, 71.7, 115.9, 115.9, 119.9, 119.9, 130.9, 148.0, 154.7, 170.0; EI+m/z (MH+): 319; and IR spectra on KBr at 1523, 1555, 1656, 1731, 2830, 2926, 2968 and 3311 cm'1.
The isolated desfluoro linezolid of the present invention may be characterized by a 1H NMR, substantially as depicted in figure 2. The isolated desfluoro linezolid of the present invention may be characterized by 13C NMR, substantially as depicted in figure 3. The isolated desfluoro linezolid of the present invention may be characterized by an IR spectrum substantially as depicted in figure 4. The isolated, desfluoro linezolid of the present invention may be characterized by an Mass spectrum substantially as depicted in figure 5. The isolated desfluoro linezolid of the present invention may be prepared by performing the process described in U.S. Patent No. 5,688,792, with l-fluoro-4- nitrobenzene instead of 3,4-difluoronitrobenzene, according to the following scheme:
Figure imgf000009_0001
Desfluoro Linezolid
The desfluoro linezolid of the present invention is isolated by a process comprising the following steps; a) combining (5R)-[[3-[4-(4-morpholinyl)phenyl]-2- oxo-5-oxazolidinyl]methyl]azide with an organic solvent, preferably a C1-C4 alkyl ester or a C6 to C12 aromatic hydrocarbon, more preferably toluene or ethylacetate, most preferably toluene, and hydrogen gas in the presence of a catalyst to obtain a reaction mixture containing (5S)-[[3-[4-(4-morpholinyl)phenyl]-2-oxo-5- oxazolidinyl]methyl] amine; b) filtering the reaction mixture to obtain a solution containing (5S)-[[3-[4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl}methyl]amine; c) adding acetic anhydride to the solution to obtain a precipitate; and d) recovering and drying the precipitate to obtain isolated desfluoro linezolid. Preferably, recovering of the precipitate in step d) is carried out by filtering or decanting. Preferably, the catalyst in step a) is selected from the group consisting of Pd/C, Raney Nickel, and noble metal catalysts, more preferably the catalyst is Pd/C. The isolated desfluoro linezolid of the present invention is useful as a reference marker for linezolid. As such, it may be used in order to detect the desfluoro linezolid impurity in a linezolid sample.
Step 7. Preparation of N-rr(5S)-3-r4-(4-moφholinyl)phenyl1-2-oxo-5- oxazolidinyl]methyl1acetamide (des-fluoro-linezolid). In a IL reactor, 6 g (5R)-[[ 3-(4-morpholinyl)phenyl]-2-oxo-5- oxazolidinyl]methyl]azide were charged with 0.7L toluene followed by 0.6 g Pd/C (10% Pd/C containing 52% water). The system was bubbled with ammonia (gas) during 2 h, and then flushed three times with nitrogen and 3 times with hydrogen. The pressure of hydrogen was set to 1.5 arm. The reaction mixture was stirred at RT and the reaction followed up until completion. The reaction mixture was filtered and the solution was treated with 60 ml acetic anhydride at RT. The precipitate was filtered and dried to obtain 3.3 g of desfluoro linezolid (purity: 99.3%). Desfluorolϊnezolid 1H-NMR and 13C-NMR identification
Figure imgf000015_0001
Figure imgf000015_0002

...................

http://www.google.com/patents/US6559305

Example 1 Preparation of Crystal Form II of Linezolid
Linezolid with better than 99.8% enantiomeric purity, less than 0.2% of the R enantiomer, (1.99 grams) is mixed with ethyl acetate (100 mL). The flask is stoppered and heated to 65° with constant stirring in a temperature controlled oil bath. The linezolid is completely dissolved and the mixture is stirred for an additional 10 minutes. The temperature is maintained at 55° in the flask and one neck of the flask is unstoppered to allow slow evaporation of the solvent. A gentle stream of nitrogen is blown across the open neck to aid in evaporation. Solids spontaneously precipitated from solution and the volume is reduced by about 25% of the initial volume. The flask is sealed and mixed for 90 minutes while maintaining the mixture at 55°. The mixture was then cooled to about 23° while being stirred. The solids are isolated by vacuum filtration using a sintered glass funnel to give linezolid in crystal form. Analysis by powder X-ray diffraction indicates that the solids are linezolid crystal Form II.






........................


http://www.google.com/patents/US7989618

Example 1 Linezolid Dihydrochloride
20 g of linezolid are dissolved in 750 ml of acetone at about 30° C. The solution is kept at about 30° C. and 8 ml of concentrated hydrochloric acid (37% w/w aqueous solution) are added, thus immediately causing linezolid dihydrochloride to precipitate as a white solid. The mixture is kept under stirring at about 30° C. for approximately 30 minutes, then refluxed under stirring for about 2 hours. The mixture is left to cool to room temperature, then cooled on ice-water bath, under stirring, for about 2 hours. A white solid precipitates which is filtered with suction, washed with 30 ml of acetone and dried under vacuum at about 50° C.
A solid water-soluble crystalline product is obtained, characterized by an XRPD spectrum substantially as reported in FIG. 3, wherein the most intense diffraction peaks fall at 13.9; 18.2; 19.1; 19.7; 22.2; 22.9; 23.6; 25.3; 27.1; 28.4±0.2° in 2θ; and by a DSC thermogram substantially as reported in FIG. 4, characterized by an exothermic peak around 178±2° C. The acid-base potentiometric titre is double while the argentimetric one is 17.71% (theor. dihydrochloride 17.77%). Purity 99.8% as determined by HPLC.
1H NMR (300 MHz, DMSO-d6), ppm: 8.37 (bt, 1H), 7.50 (dd, 1H, J=15.3 Hz, J=2.7 Hz), 7.10 (m, 2H), 4.68 (m, 1H), 4.05 (t, 1H, J=9.0 Hz), 3.70 (m, 5H), 3.36 (t, 2H, J=5.1 Hz), 3.07 (t, 4H, J=4.5 Hz), 1.80 (s, 3H).
..............................................

http://www.google.com/patents/EP2690100A1?cl=en

    Example 3
  • [0034]
    To a 25 ml, round-bottomed flask equipped with a magnetic stirring bar was charged "amine" (0.49 g) followed by water (8.30 ml). A heterogeneous mixture was stirred and hydrochloric acid (0.12 mL, 35 %) was added. A homogenous solution was obtained. The solution was cooled down in an ice-water bath to 0°C. Acetic anhydride (0.31 mL) was added followed by sodium bicarbonate (0.45 g). Carbon dioxide was immediately released and a formation of white precipitate was observed. The precipitate was filtered off and the filter cake was washed with water (10 ml). The filter cake was collected and dried (100 mbar) at 70°C overnight. An off-white solid linezolid (0.26 g) was isolated.

................................
PATENT

http://www.google.com/patents/WO2007116284A1?cl=en


Example 3 Preparation of (S)~N-[3-(3-fiuoro~4~morpholin-4-yI-ρhenyI)~2-oxo- oxazolidin-5~ylmethyl]-acetarnide (Linezo!id)
Figure imgf000011_0001
Method A
To (S)-5-{[(4-chloro-benzylidene)-amino]-methyl}-3-(3-fluoro-4-morpholin-4-yl- phenyl)-oxazolidin-2-one (129.5g, 31 mmol, 1.0 eq.) is added ethyl acetate (935 mL) and water (935 mL). To the heterogeneous mixture is added 12M aq. HCl (51.58 mL, 620 mmol, 2.0 eq.). Within minutes, the solid went into solution and the reaction mixture is biphasic. After stirring the emulsion at ambient temperature for 2 hours, HPLC assay showed the hydrolysis reaction to be complete (HPLC conditions: YMC 5μ ODS-AM 150 nm X 4.6 nm column, eluting with CH3CN /water + 0.1% TFA from 20% CH3CN to 80% CH3CN in 8 min at 0.5 mL/min, detecting at 254nm, Retention time of (S)-N-[3-(3-fluoro-4-morpholin-4-yl- phenyl)-2-oxo-oxazolidin-5-ylmethyl]-amine is 3.2 min). The phases are separated, the organic layer is discarded, and the aqueous layer is washed with ethyl acetate (500 mL). CH2Cl2 (900 mL) is added and the pH is adjusted to 6.7 with ~ 25 mL aq. 50% aq. NaOH. With constant stirring, Ac2O (58.49 mL, 620 mmol, 2.0 eq.) is added in one portion and the pH dropped to 2. The pH is then readjusted to 6 using 50% aq. NaOH. The pH is adjusted to ca. 7.1 with 50% aq. NaOH and the phases separated. The aqueous phase is extracted with CHiCl2 (800 mL) and the organics are combined and concentrated to ~1L in volume. Ethyl acetate (IL) is added and the volume is reduced to 1.5 L under vacuum. Another IL of ethyl acetate is added and volume is reduced again to IL under vacuum. The resultant slurry is cooled to 00C and the precipitate collected by vacuum filtration. The resulting solid is washed with ethyl acetate (250 mL). The crude product is dried under vacuum at 500C for 2 hours to give the title compound as Hnezolid crystalline Form I.
Figure imgf000012_0001
Following the general procedure of method A and making non-critical variations, but substituting (S)-5- { [2,4-dichloro-benzylidene)-amino]-methyl } -3-(3-fluoro-4-morphoIin-4-yl- phenyl)-oxazolidin-2-one (example 11) for (S)-5-{[(4-chloro-benzylidene)-amino]- methyl}-3-(3-fluoro-4-morρholin-4-yl-phenyl)-oxazolidin-2-one, the title compound is obtained.
Figure imgf000012_0002
Following the general procedure of method B and making non-critical variations, but substituting (S)-5-{ [4-bromo-benzylidene)-amino] -methyl }-3-(3-fluoro-4-morpholin-4-yl~ phenyl)-oxazolidin-2-one (example 9) for (S)-5-{[(4-chloro-benzylidene)-amino]- methyl}-3-(3-fluoro-4-morph.olin-4-yl-phenyl)-oxazoIidin-2-one, the title compound is obtained.


Example 4 Trituration (convert linezolid crystalline Form I to linezolid crystalline Form E) The product from Example (89.18 g) is transferred to a 3L round bottom flask equipped with a mechanical stirrer, thermocouple and heating mantel. Ethyl acetate (2.23 L, 15 mL/g) is added and seeded with Linezolid form II crystals and the slurry is heated to ca. 500C. A slight exotherm of 30C is observed. After 30 minutes of heating the form change is observable as the solid is changing to long needles. Stirring is continued for 2 hours at 500C, at which time the contents are cooled to ambient temperature and stirred for an additional 30 minutes. The contents are then cooled to 30C for 1.5 hours, filtered and washed with cold ethyl acetate (300 mL total). The resultant solids are dried under vacuum at 50°C for 18 hours to give Linezolid (78.12 g) Form II by XRD, 99.8 wt%, 99.9% ee. HPLC conditions: YMC 5μ ODS-AM 150 nm X 4.6 nm column, etuting with CH3CN /water + 0.1% TFA from 20% CH3CN to 80% CH3CN in 8 min at 0.5 mL/min, detecting at 254nm. TR (Linezolid) = 4.4 min; HPLC conditions: Chiralcel OJ-H 250 nm X 4.6 nm column, eluting with 90% CO2/ 10%MeOH at 3.0 mL/min, detecting at 255 nm. TR [title compound] = 3.6 min; TR (enantiomer of title compound) = 4.1 rain
............................................

http://www.google.com/patents/EP2516408A1?cl=en

The polymorphic form obtained by following process disclosed in U.S. Pat. No. 5,688,792 is designated as Form I. Figure- 1 depicts the PXRD graph of Form I obtained by following prior art process. [15] Disadvantage of the process disclosed in U.S. Pat. No. 5,688,792 is that it involves use of n-butyl lithium. Due to its explosive nature it is difficult to handle at plant scale. Also, the said reaction is carried out at temperature of -78°C, which is difficult to attain during commercial production. Further the intermediate obtained requires purification by column chromatography. Column chromatography is a cumbersome technique and difficult to practice during commercial scale production. 
The process for the preparation of Linezolid is also disclosed in Journal of Medicinal Chemistry (1996), 39(3), 673-9, U.S. Pat. Nos. 6,492,555, 5,837,870, 6,887,995, 7,307,163, 7,429,661, etc.





Linezolid was first disclosed in U.S. Pat. No. 5,688,792. The process for synthesis is as disclosed in Scheme-I







The synthetic reaction scheme of the present invention is as shown below.
Figure imgf000013_0001
Scheme-ll

Example 6: Synthesis of Linezolid Crude.
[140] Ethyl acetate (3500ml) and 10% palladium on carbon catalyst (6.0g) are added in autoclave having (R)- [N- 3 - (3 -Fluoro-4-morpholinylphenyl) -2-oxo- 5 -oxazolidinyl] methyl azide (lOOg) at 20-30°C. Cool the reaction mass & maintain 2-3kg hydrogen pressure at 15-20°C for 6-7 hrs. Filter it & wash the hyflo bed by Ethyl acetate
(100mlx2). Then add the Triethyl amine (35. lg) & Acetic anhydride (29.9g) slowly at 25-30°C under stirring. Cool the mix, filter it and wash the solid with chilled (0-5°C) Ethyl acetate (100 ml) followed by water (100mlx2). Finally product is dried at 55-60° C. Yield: 0.85.: Percentage 81%w/w.
[141]
[142] Example 7: Synthesis of Linezolid Pure
[143] Reflux the Acetone (1020ml) and Linezolid crude (lOOg) at 55-60°C for the 30
minutes. Filter the hot turbid solution & wash it with hot (55-60°C) acetone (50ml). Cool the reaction mixture at -5 to 0°C for 1 hour, wash the solid with chilled (-5 to 0°C) acetone (50ml). After drying the Linezolid semi pure (77g) add n-Propanol (308ml) reflux it at 95-100°C for 30 min & filter it by hot solution through hyflo bed. Cool the mix to 0-5°C for 1 hour and wash the solid with chilled (0-5°C) n-Propanol (77ml). Dry the material at 55-60°C. Yield: 0.73.: Percentage 73%w/w.
[144]
[145] Example 8: Synthesis of Linezolid
[146] Ethyl acetate (3500ml) and 10% palladium on carbon catalyst (6.0g) are added in autoclave having (R)- [N- 3 - (3 -Fluoro-4-morpholinylphenyl) -2-oxo- 5 -oxazolidinyl] methyl azide (lOOg) at 20-30°C. Cool the reaction mass & maintain 2-3kg hydrogen pressure at 15-20°C for 6-7 hrs. Filter it & wash the hyflo bed by Ethyl acetate. Distill out ethyl acetate at 75-90°C and then cool the reaction mass to 0-5°C. Add acetone (1000ml) & acetic anhydride (29.9g) at 0-5°C. Further, add Triethyl amine (37.8g) slowly at 0-5°C under stirring. Maintain the reaction mass at 0-5°C for 1-2 hrs. Heat the reaction mass to reflux at 65-75°C for 1 hr. Again cool the reaction mass to 0-5°C fori hr. Filter the solid wash it with acetone and water and dry it at 55-60C. Yield: 0.80.: Percentage 80 w/w.
 Example 9: Synthesis of Linezolid Form I
[149] Reflux n-propanol (400ml) and Linezolid (lOOg) at 95-100°C till all solid gets
dissolved. Add activated charcoal (2.0g) and heat for 30 mins. Filter thro hyflo bed. Heat the filtrate and concentrate the solution by partially removing n-propanol. Cool to 0-5°C and filter the solid and dry it at 55-60°C under vacuum. Yield: 0.9. : Percentage 90 w/w.


...............................................
https://acs.confex.com/acs/green08/techprogram/P52019.HTM

Wednesday, June 25, 2008 - 2:00 PM
New York (Capital Hilton)
128

Convergent Green Synthesis of Linezolid (Zyvox)

William R. Perrault, James B. Keeler, William C. Snyder, Christian L. Clark, Michael R. Reeder, Richard J. Imbordino, Rebecca M. Anderson, Nabil Ghazal, Stephen L. Seacrest, and Bruce A. Pearlman. Pfizer, Kalamazoo, MI
Pfizer has developed a novel, convergent, green, second generation synthesis of Linezolid (the active ingredient in ZyvoxTM). The second generation process will replace the launch process after approval by appropriate regulatory agencies and has numerous green chemistry benefits: overall yield is increased by 8%; total waste is reduced by 56%; non-recycled w is eliminated. At current volumes, total waste will be reduced 1.9 million kilograms per year and 1.7 million kg per year non-recyclable waste will be eliminated. The improved process utilizes a highly efficient low dilution convergent synthesis to replace the more dilute linear synthesis utilized in the launch process. The key chlorohydrin imine reagent 1 contains both the chiral center and the key 5-S-aminomethyl moiety of linezolid. In the launch process, S-1-chloro-2,3-propanediol was utilized to install the oxazolidinone functionality. However, this yielded a 5-S-hydroxymethyl group which required activation as the 3-nitrobenzenesulfonate and displacement with excess ammonia to generate the corresponding aminomethyl group of linezolid. The second generation process affords the oxazolidinone imine 3 in the convergent step. The penultimate 5-S-aminomethyl oxazolidinone 4 is then easily formed via hydrolysis with stoichiometric hydrochloric acid. Acylation of this amine with acetic anhydride, utilizing an improved Schotten Baumann reaction, affords high purity linezolid.



........................................




............................................





..............................................

http://www.google.com/patents/EP2072505A2?cl=en
  • WO 95/07271 , which specifically describes the synthesis of linezolid, namely [(S)-N-[[3-(3-fluoro-4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide], according to the following scheme:
    Figure imgb0001
  • [0003]
    Other synthetic routes for the preparation of linezolid are reported for example in US 6107519 and in Tetrahedron Letters, Vol 37, N° 44, pages 7937-7940, wherein the chiral compound shown below is used instead of glycidyl butyrate as a synthon containing the molecule stereocenter.
    Figure imgb0002
  • [0004]
    It should be appreciated that all of the known approaches to the preparation of linezolid make use of chiral synthons for the construction of the stereocenter. These are small molecules characterized by a high cost, therefore they are not suitable for the production of the compound on an industrial scale.
  • [0005]
    There is therefore the need for an alternative synthesis which provides oxazolidinone derivatives, linezolid included, from inexpensive starting materials, and which does not require a chiral synthon for the construction of the molecule, so that it can be used for the industrial preparation of such derivatives.



........................................

http://pubs.rsc.org/en/content/articlelanding/2010/md/c0md00015a/unauth






........................................





................................................





.......................................

RSC Adv., 2013,3, 24946-24951

DOI: 10.1039/C3RA45186K



http://pubs.rsc.org/en/content/articlelanding/2013/ra/c3ra45186k#!divAbstract









Graphical abstract: Concise asymmetric synthesis of Linezolid through catalyzed Henry reaction
A new asymmetric synthesis of the antibiotic Linezolid was performed through a copper-catalyzed Henry reaction as the key step. The use of camphor-derived aminopyridine ligands helped to improve the yields of the chiral precursor and to obtain Linezolid in good overall yield and enantiomeric excess.



Linezolid 1. Mp: 181–182 C [lit. 181.5–182.5 C];
1 H-NMR (300 MHz; CDCl3) d 2.02 (s, 3H), 3.06 (t, J ¼ 4.7 Hz, 4H), 3.61– 3.78 (m, 3H), 3.87 (t, J ¼ 4.7 Hz, 4H), 4.03 (t, J ¼ 9.0 Hz, 1H), 4.72–4.82 (m, 1H), 6.17 (bt, 1H, exch. with D2O), 6.93 (t, J ¼ 9.0 Hz, 1H), 7.08 (dd, J1 ¼ 9.0 Hz, J2 ¼ 2.5 Hz, 1H), 7.44 (dd, J1 ¼ 14.4 Hz, J2 ¼ 2.5 Hz, 1H); ee ¼ 71%;

HPLC (Daicel CHIRALPAK-IA, hexane/i-PrOH ¼ 70 : 30, ow rate 0.8 mL min 1 , l ¼ 254 nm); tR (major) ¼ 14.1 min; tR (minor) ¼ 16.4 min. A true sample of (S)-Linezolid (ee > 98%) under the same HPLC conditions gave a tR ¼ 14.1 min.






......................................
http://www.slideshare.net/vishwajeeta/introduction-new-ppt
http://www.slideshare.net/vishwajeeta/introduction-new-ppt

....................................




http://www.slideshare.net/pushechnikov/linezolid-case-study

.......................................

http://pubs.rsc.org/en/content/articlelanding/2011/cc/c1cc15503b#!divAbstract






.......................................

http://www.mdpi.com/1424-8247/3/7/1988/htm

Pharmaceuticals 03 01988 g001 1024



....................................




Numbered structure of linezolid, showing the pharmacophore required for good activity (in blue) and desirable structural features (in orange).


Title: Linezolid
CAS Registry Number: 165800-03-3
CAS Name: N-[[(5S)-3-[3-Fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide
Manufacturers' Codes: PNU-100766; U-100766
Trademarks: Zyvox (Pharmacia & Upjohn); Zyvoxid (Pharmacia & Upjohn)
Molecular Formula: C16H20FN3O4
Molecular Weight: 337.35
Percent Composition: C 56.96%, H 5.98%, F 5.63%, N 12.46%, O 18.97%


Literature References: Prototype of the oxazolidinone antimicrobials; inhibits bacterial mRNA translation. Prepn: M. R. Barbachyn et al., WO 9507271 (1995 to Upjohn); eidem, US 5688792 (1997 to Pharmacia & Upjohn); S. J. Brickner et al., J. Med. Chem. 39, 673 (1996). 

Antibacterial spectrum: C. W. Ford et al., Antimicrob. Agents Chemother. 40, 1508 (1996). Mechanism of action study: D. L. Shinabarger et al., ibid. 41, 2132 (1997).

 HPLC determn in plasma: C. Buerger et al., J. Chromatogr. B 796, 155 (2003). Clinical comparison with vancomycin, q.v., for MRSA infections: D. L. Stevens et al., Clin. Infect. Dis. 34, 1481 (2002). 

Review of pharmacology: L. D. Dresser, M. J. Rybak, Pharmacotherapy 18, 456-462 (1998); and clinical experience: R. Norrby, Expert Opin. Pharmacother. 2, 293-302 (2001).


Properties: White crystals from ethyl acetate and hexanes, mp 181.5-182.5°. [a]D20 -9° (c = 0.919 in chloroform).
Melting point: mp 181.5-182.5°
Optical Rotation: [a]D20 -9° (c = 0.919 in chloroform)
Therap-Cat: Antibacterial.
Keywords: Antibacterial (Synthetic); Oxazolidinones.


Linezolid
Skeletal formula of linezolid
Linezolid-from-xtal-2008-3D-balls.png
Systematic (IUPAC) name
(S)-N-({3-[3-fluoro-4-(morpholin-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)acetamide
Clinical data
Trade namesZyvox, Zyvoxam, Zyvoxid
AHFS/Drugs.commonograph
MedlinePlusa602004
Licence dataUS FDA:link
  • AU: C
  • US: C
Intravenous infusion, oral
Pharmacokinetic data
Bioavailability~100% (oral)
Protein bindingLow (31%)
MetabolismHepatic (50–70%, CYPnot involved)
Half-life4.2–5.4 hours (shorter in children)
ExcretionNonrenal, renal, and fecal
Identifiers
165800-03-3 Yes
J01XX08
PubChemCID 441401
DrugBankDB00601 
ChemSpider390139 Yes
UNIIISQ9I6J12J Yes
KEGGD00947 Yes
ChEMBLCHEMBL126 Yes
NIAID ChemDB070944
Chemical data
FormulaC16H20FN3O4
337.346 g/mol



Cited PatentFiling datePublication dateApplicantTitle
WO1995007271A1 *Aug 16, 1994Mar 16, 1995Michael R BarbachynSubstituted oxazine and thiazine oxazolidinone antimicrobials
AU2001100437A4 *Title not available
EP0963980A2 *Mar 10, 1999Dec 15, 1999The Wellcome Foundation Limited1,2,4-Triazine derivative, its preparation and its use as reference marker for testing purity and stability of "lamotrigine"


Reference
1*[Online] August 2002 (2002-08), XP002388488 Retrieved from the Internet: URL:www.emea.eu.int/pdfs/human/ich/273799e n.pdf> [retrieved on 2006-07-03]
2*[Online] June 1995 (1995-06), XP002388489 Retrieved from the Internet: URL:www.emea.eu.int/pdfs/human/ich/38195en .pdf> [retrieved on 2006-07-03]
3*DATABASE CA [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; LIU, JUN ET AL: "Preparation of oxazolidone derivatives as antibacterial agents" XP002429969 retrieved from STN Database accession no. 2003:576097 -& CN 1 355 165 A (INSTITUTE OF MEDICAL AND BIOLOGICAL TECHNOLOGY, CHINESE ACADEMY OF MED) 26 June 2002 (2002-06-26)
4*GLEAVE D M ET AL: "Synthesis and antibacterial activity of [6,5,5] and [6,6,5] tricyclic fused oxazolidinones" BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 8, no. 10, 19 May 1998 (1998-05-19), pages 1231-1236, XP004137053 ISSN: 0960-894X
5*REDDY K V S R K ET AL: "Isolation and characterization of process related impurities in linezolid" JOURNAL OF PHARMACEUTICAL AN BIOMEDICAL ANALYSIS, vol. 30, no. 3, 15 October 2003 (2003-10-15), pages 635-642, XP002388486

WO2001057035A1 *Jan 29, 2001Aug 9, 2001Upjohn CoLinezolid-crystal form ii
WO2002032857A1 *Oct 17, 2001Apr 25, 2002Robert C GadwoodMethods of producing oxazolidinone compounds
WO2002085849A2 *Apr 15, 2002Oct 31, 2002Delara B GodrejProcess to prepare oxazolidinones
WO2005099353A2 *Apr 19, 2004Oct 27, 2005Reddy Pingili KrishnaA novel process for the preparation of linezolid and related compounds
WO2006008754A1Jul 20, 2004Jan 26, 2006Reddy Pingili KrishnaNovel intermediates for linezolid and related compounds
WO2006031179A1 *Sep 12, 2005Mar 23, 2006Astrazeneca AbProcess for preparation of phtalimide
WO2007116284A1 *Mar 26, 2007Oct 18, 2007Pfizer Prod IncProcess for preparing linezolid
WO2010081404A1Jan 8, 2010Jul 22, 2010Lianhe Chemical Technology Co., Ltd.Method for preparing linezolid and intermediates thereof
WO2012019632A1Aug 11, 2010Feb 16, 2012Synthon B.V.Process for making linezolid
WO2012019862A1Jul 14, 2011Feb 16, 2012Synthon B.V.Process for making linezolid
WO2012114354A1Feb 21, 2012Aug 30, 2012Lee Pharma LimitedAnhydrous linezolid crystalline form-ii
WO2013072923A1Sep 18, 2012May 23, 2013Cadila Healthcare LimitedProcess for the preparation of crystalline linezolid
WO2013111048A1Jan 22, 2013Aug 1, 2013Jubilant Life Sciences LimitedImproved process for the preparation of stable crystalline form-i of linezolid, substantially free of residual solvent
WO2014071990A1Nov 9, 2012May 15, 2014Synthon BvProcess for making linezolid
EP1403267A1 *Sep 25, 2003Mar 31, 2004Daiso Co., Ltd.Process for preparing glycidylphthalimide
EP1564215A1 *Sep 25, 2003Aug 17, 2005Daiso Co., Ltd.Process for preparing glycidylphthalimide
EP2100884A1Oct 16, 2003Sep 16, 2009Symed Labs LimitedCrystalline form of linezolid
EP2690100A1Jul 14, 2011Jan 29, 2014Synhton B.V.Process for making linezolid
US6444813Jan 29, 2001Sep 3, 2002Pharmacia & Upjohn CompanyMixing linezolid of an >98% enantomeric purity in a solvent at >80 degrees; separating a crystal (ii) of >99% purity; analysis by the powder x-ray diffraction spectrum/infrared spectrum as a mineral oil mull; bactericides; stability
US6514529Mar 15, 2001Feb 4, 2003Pharmacia & Upjohn CompanyA compressed tablet of antibacterial oxazolidinone selected from the group consisting of linezolid, eperezolid and (S)-N-((3-(3-fluoro-4-(tetrahydro-2H-thiopyran-4-yl)phenyl-2-o xo-5-oxazolidinylmethyl)acetamide S,S-dioxide
US6544991Jun 21, 2001Apr 8, 2003Pharmacia & Upjohn CompanyCompositions and methods for treating bacterial infections
US6559305May 23, 2002May 6, 2003Pharmacia & Upjohn CompanyLinezolid—crystal form II
US6617339Jun 3, 1999Sep 9, 2003Syngenta LimitedOxazolidinone derivatives, process for their preparation and pharmaceutical compositions containing them
US6796975Mar 15, 2001Sep 28, 2004Pharmacia & Upjohn CompanyContainer for linezolid intravenous solution
US6833453Oct 17, 2001Dec 21, 2004Pharmacia & Upjohn CompanyAs an example, manufacturing a 5-(tert-butylcarbamoyl)-amino-methyl-oxazolidinone by condensing a carbamate with a tert-butylcarbamoyl protected derivative of glycidylamine or a 3-amino-1-halopropanol
US6875875Sep 25, 2003Apr 5, 2005Daiso Co., Ltd.Process for preparing glycidylphthalimide
US6887995Apr 15, 2002May 3, 2005Pharmacia & Upjohn CompanyReacting N-aryl-O-alkylcarbamate with an amide derivative in the presence of a lithium cation, a base, and a nucleophile
US6989381Aug 20, 2001Jan 24, 2006Pharmacia CorporationContaining s cyclodextrin compound in a concentration sufficient to maintain the drug in solution at such a drug concentration.
US7087784Mar 25, 2004Aug 8, 2006Pharmacia & UpjohnProcess to prepare oxazolidinones
US7128928Feb 20, 2003Oct 31, 2006Pharmacia CorporationOphthalmic formulation with novel gum composition
US7135576Jan 7, 2005Nov 14, 2006Daiso Co., Ltd.Process for preparing glycidylphthalimide
US7307163Apr 19, 2004Dec 11, 2007Symed Labs LimitedProcess for the preparation of linezolid and related compounds
US7351824Oct 8, 2007Apr 1, 2008Symed Labs LimitedIntermediates for oxazolidinone antibacterials; N-[3-Chloro-2-(R)-hydroxypropyl]-3-fluoro-4-morpholinyl aniline
US7429661Jul 20, 2004Sep 30, 2008Symed Labs LimitedIntermediates for linezolid and related compounds
US7524954Oct 8, 2007Apr 28, 2009Symed Labs LimitedReacting 3-fluoro-4-morpholinyl aniline derivative with epichlorohydrin; converting chloromethyl oxazolidinone to aminomethyl oxazolidinone; carbonylation ; reacting with potassium phthalimide, hydrazine hydrate, and acetic anhydride; cyclization, carbamylation
US7714128Oct 16, 2003May 11, 2010Symed Labs Limitedcrystalline linezolid form III (N-[[(5S)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide) an antibacterial agent; thermal stability
US7718799Sep 26, 2007May 18, 2010Symed Labs LimitedCrystalline form of linezolid
US7718800Sep 26, 2007May 18, 2010Symed Labs LimitedPrepared by mixing linezolid with solvent or mixture of solvents, cooling contents to below 15 degrees C., optionally seeding contents with linezolid form III, stirring, and collecting linezolid form III crystals by filtration or centrifugation; antibacterial agent; thermally stable
US7732597Sep 26, 2007Jun 8, 2010Symed Labs LimitedPrepared by acetylating (S)-N-[[3-[3-fluoro-4-[4-morpholinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]amine in a solvent, optionally in presence of an organic base to form linezolid, seeding reaction mixture, and isolating linezolid form III; antibacterial agent; thermally stable
US7741480Oct 8, 2007Jun 22, 2010Symed Labs LimitedProcess for the preparation of linezolid and related compounds
US8658789Jan 8, 2010Feb 25, 2014Lianhe Chemical Technology Co., Ltd.Method for preparing linezolid and intermediates thereof
US5837870Mar 28, 1997Nov 17, 1998Pharmacia & Upjohn CompanyProcess to prepare oxazolidinones
US6107519Oct 13, 1998Aug 22, 2000Pharmacia & Upjohn CompanyAmido-substituted secondary alcohol intermediates and preparation thereof
US6444813Jan 29, 2001Sep 3, 2002Pharmacia & Upjohn CompanyMixing linezolid of an >98% enantomeric purity in a solvent at >80 degrees; separating a crystal (ii) of >99% purity; analysis by the powder x-ray diffraction spectrum/infrared spectrum as a mineral oil mull; bactericides; stability
US6492555Jan 15, 2002Dec 10, 2002Pharmacia & Upjohn CompanyReaction of a carbamate with either a (s)-secondary alcohol or (s)-epoxide or (s)-ester; bactericides
US6559305May 23, 2002May 6, 2003Pharmacia & Upjohn CompanyLinezolid—crystal form II
US6716980Jun 27, 2003Apr 6, 2004Pharmacia & Upjohn CompanyCyclization and acylation of carbamate
US6740754Apr 24, 2003May 25, 2004Pharmacia & Upjohn CompanyProcess to produce oxazolidinones
US6833453Oct 17, 2001Dec 21, 2004Pharmacia & Upjohn CompanyAs an example, manufacturing a 5-(tert-butylcarbamoyl)-amino-methyl-oxazolidinone by condensing a carbamate with a tert-butylcarbamoyl protected derivative of glycidylamine or a 3-amino-1-halopropanol
US6887995Apr 15, 2002May 3, 2005Pharmacia & Upjohn CompanyReacting N-aryl-O-alkylcarbamate with an amide derivative in the presence of a lithium cation, a base, and a nucleophile
US7649096 *Jul 17, 2006Jan 19, 2010Glenmark Pharmaceuticals Limitedcrystallization of linezolid antibacterial agent in solvent and antisolvent
US20060111350Jun 29, 2005May 25, 2006Judith AronhimeSolid forms of linezolid and processes for preparation thereof
US20060142283Jun 29, 2005Jun 29, 2006Judith AronhimeCrystalline form IV of linezolid
US20090156806Dec 11, 2008Jun 18, 2009Dipharma Francis S.R.I.Process for the Preparation of Oxazolidinone Derivatives
WO1995007271A1Aug 16, 1994Mar 16, 1995Michael R BarbachynSubstituted oxazine and thiazine oxazolidinone antimicrobials
WO2005035530A1Oct 16, 2003Apr 21, 2005Reddy Pingili KrishnaA novel crystalline form of linezolid
WO2007026369A1Aug 29, 2005Mar 8, 2007Reddy Pingili KrishnaA novel amorphous form of linezolid
Citing PatentFiling datePublication dateApplicantTitle
WO2009032294A2 *Sep 5, 2008Mar 12, 2009Teva PharmaProcesses for the preparation of a linezolid intermediate, linezolid hydroxide
WO2011076678A1 *Dec 17, 2010Jun 30, 2011F. Hoffmann-La Roche AgSubstituted benzamide derivatives
...............


S. : The views expressed are my personal and in no-way suggest the views of the professional body or the company that I represent.
P.S. : The views expressed are my personal and in no-way suggest the views of the professional body or the company that I represent.
P.S. : The views expressed are my personal and in no-way suggest the views of the professional body or the company that I represent.



COCK WILL TEACH YOU NMR



COCK SAYS MOM CAN TEACH YOU NMR





Join me on Linkedin

View Anthony Melvin Crasto Ph.D's profile on LinkedIn

Join me on Facebook FACEBOOK
Join me on twitterFollow amcrasto on Twitter     
Join me on google plus Googleplus

         

 amcrasto@gmail.com



JAFFNA SRILANKA



Map of jaffna sri lanka


Image result for JAFFNA